HCPCS Level II code J7324 represents a single dose of hyaluronan derivative (Orthovisc) administered by intra-articular injection for viscosupplementation. This code is used nationally to bill for a non-opioid, intra-articular therapy commonly applied in the management of joint pain, particularly degenerative joint disease. Its use affects outpatient and office-based musculoskeletal care delivery and has implications for procedure billing, medical necessity review, and payer coverage policies.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical purpose and service context, along with national benchmarking elements where available. The publication outlines common billing considerations, payer coverage patterns, and coding relationships relevant to musculoskeletal and rheumatologic care.

This summary prepares clinicians, coders, and policy analysts to understand where J7324 fits within procedure billing, the typical settings in which the service is delivered, and the policy considerations that influence reimbursement and utilization. Data not available in the input is noted where applicable in subsequent sections.